Mibeg (Iodine (123i) Iobenguane)

Iobenguane is a norepinephrine analog labeled with iodine‑123. After intravenous injection it is taken up by adrenergic nerve terminals via the norepinephrine transporter (NET). The radiolabel emits gamma photons, allowing SPECT imaging of tissues that store or release norepinephrine, thereby revealing sympathetic activity.

The exact activity (megabecquerels) and volume are determined by the prescribing nuclear medicine physician based on patient weight, age, and the specific imaging protocol. The prescriber calculates the appropriate administered dose and prepares the injection immediately before the procedure.

Safety data for Iobenguane I‑123 in pregnant or lactating women are limited. Because the radiotracer can cross the placenta and may be secreted in breast milk, it is generally avoided unless the diagnostic benefit outweighs the potential risk. The prescriber should assess each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The main alternative for sympathetic nerve imaging is metaiodobenzylguanidine labeled with iodine‑131 (I‑131 MIBG). I‑123 provides higher image quality, lower radiation dose, and faster imaging times compared with I‑131, making Mibeg preferable for many diagnostic protocols, though availability and regulatory status may differ.

Mibeg must be stored refrigerated at 2–8 °C in its original shielding container, protected from light, and must not be frozen or shaken. Prior to use, the vial should be inspected for any particulate matter or discoloration, and handled with radiation safety precautions in a designated radiopharmacy area.

Mibeg is supplied as a sterile solution for injection. The prescribed activity is drawn into a shielded syringe and administered intravenously, typically as a slow bolus or short infusion under aseptic conditions. Imaging is performed shortly after injection, according to the specific nuclear medicine protocol.

Serious risks include severe allergic reactions (anaphylaxis), marked hypotension, radiation‑induced thyroiditis, and rare radiation‑related tissue injury. Patients should be monitored for signs of hypersensitivity, blood pressure changes, and any unexpected symptoms during and after the procedure, and appropriate emergency measures should be available.

Mibeg is contraindicated in individuals with known hypersensitivity to Iobenguane, iodine, or any component of the formulation. It should also be avoided in patients with uncontrolled hypertension, severe cardiac arrhythmias, or those who are pregnant or breastfeeding unless the diagnostic benefit justifies the potential risk.